Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- 21 March 2012
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (8) , 2233-2240
Abstract
Ipilimumab is a fully human monoclonal antibody which blocks cytotoxic T-lymphocyte antigen-4, an immune checkpoint molecule that down-regulates pathways of T-cell activation. Ipilimumab has demonstrated a statistically significant improvement in overall survival in two randomized controlled phase III trials of patients with metastatic melanoma. A main complication of ipilimumab therapy is the development of inflammatory events which can occur in various organs, including the liver (i.e., hepatitis). Hepatic injury is a concern because it can develop with little warning and may potentially be severe. We analyzed liver biopsy findings in 4 cases of ipilimumab treatment-related hepatitis and compared them to a fifth, previously reported case. All 5 patients had a histologic pattern of injury that was similar to what is observed with acute viral and autoimmune hepatitis; however, the findings are not specific and require clinicopathologic correlation. Pathologic evidence of hepatitis resolved in all 5 patients with appropriate immunosuppressive therapy. Although a relatively uncommon adverse event with ipilimumab, patients should be monitored at regular intervals for biochemical/pathological evidence of hepatitis.Keywords
This publication has 21 references indexed in Scilit:
- The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryHepatology, 2011
- Drug-Induced Autoimmune-Like HepatitisDigestive Diseases and Sciences, 2011
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer ImmunotherapySeminars in Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer TreatmentJournal of Clinical Oncology, 2008
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell ActivationThe Oncologist, 2008
- Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse EventsThe Oncologist, 2007
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995